AU8493698A - Method for inhibiting bone resorption - Google Patents

Method for inhibiting bone resorption Download PDF

Info

Publication number
AU8493698A
AU8493698A AU84936/98A AU8493698A AU8493698A AU 8493698 A AU8493698 A AU 8493698A AU 84936/98 A AU84936/98 A AU 84936/98A AU 8493698 A AU8493698 A AU 8493698A AU 8493698 A AU8493698 A AU 8493698A
Authority
AU
Australia
Prior art keywords
dosing
bisphosphonate
unit dosage
alendronate
weekly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU84936/98A
Other languages
English (en)
Inventor
Anastasia G. Daifotis
Arthur C. Ii Santora
A. John Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU8493698(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU8493698A publication Critical patent/AU8493698A/en
Priority to AU64069/00A priority Critical patent/AU741818C/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
AU84936/98A 1997-07-22 1998-07-17 Method for inhibiting bone resorption Abandoned AU8493698A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64069/00A AU741818C (en) 1997-07-22 2000-08-28 Method for inhibiting bone resorption

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US60053351 1997-07-22
US5353597P 1997-07-23 1997-07-23
US60053535 1997-07-23
GB9717590 1997-08-20
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GB9717850 1997-08-22
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption
PCT/US1998/014796 WO1999004773A2 (en) 1997-07-22 1998-07-17 Method for inhibiting bone resorption

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU64069/00A Division AU741818C (en) 1997-07-22 2000-08-28 Method for inhibiting bone resorption
AU15677/02A Division AU1567702A (en) 1997-07-22 2002-02-18 Method for inhibiting bone resorption

Publications (1)

Publication Number Publication Date
AU8493698A true AU8493698A (en) 1999-02-16

Family

ID=27451690

Family Applications (1)

Application Number Title Priority Date Filing Date
AU84936/98A Abandoned AU8493698A (en) 1997-07-22 1998-07-17 Method for inhibiting bone resorption

Country Status (31)

Country Link
EP (5) EP1175904B8 (enExample)
JP (2) JP3479780B2 (enExample)
KR (3) KR20030097611A (enExample)
CN (3) CN1602879A (enExample)
AT (2) ATE357921T1 (enExample)
AU (1) AU8493698A (enExample)
BG (1) BG66282B1 (enExample)
BR (1) BR9810779A (enExample)
CA (1) CA2294595C (enExample)
CY (2) CY1107535T1 (enExample)
DE (6) DE69803291T2 (enExample)
DK (2) DK0998292T3 (enExample)
EA (1) EA004544B2 (enExample)
EE (1) EE05603B1 (enExample)
ES (3) ES2253136T1 (enExample)
HK (4) HK1042230A1 (enExample)
ID (1) ID24096A (enExample)
IL (1) IL133535A0 (enExample)
IS (3) IS5315A (enExample)
LU (2) LU91222I2 (enExample)
NL (2) NL300223I1 (enExample)
NO (1) NO20000323L (enExample)
NZ (1) NZ501807A (enExample)
PL (1) PL195272B1 (enExample)
PT (2) PT998292E (enExample)
SG (2) SG139556A1 (enExample)
SI (1) SI0998292T1 (enExample)
SK (1) SK932000A3 (enExample)
TR (1) TR200000145T2 (enExample)
UY (1) UY25950A1 (enExample)
WO (1) WO1999004773A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3219402B2 (ja) 1998-12-25 2001-10-15 山之内製薬株式会社 多発性骨髄腫の骨病変治療用医薬組成物
EP1178810B8 (en) * 1999-05-21 2005-07-27 Novartis AG Use of bisphosphonic acids for treating angiogenesis
EP1114642B1 (en) * 1999-07-19 2010-01-06 Toray Industries, Inc. Drugs for periodontal diseases
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
WO2001045636A1 (en) * 1999-12-20 2001-06-28 Merck & Co., Inc. Pharmaceutical kit
WO2001076577A2 (en) * 2000-04-07 2001-10-18 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
EP1591122B1 (en) * 2000-06-20 2012-09-26 Novartis AG Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
NZ567200A (en) * 2005-09-16 2010-08-27 Selamine Ltd Bisphosphonate formulation
US9592195B2 (en) * 2010-12-06 2017-03-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ATE122228T1 (de) * 1991-07-01 1995-05-15 Gergely Gerhard Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung.
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
ES2111163T3 (es) * 1992-06-30 1998-03-01 Procter & Gamble Pharma Uso de fosfonatos para el tratamiento de la osteoporosis.
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
EP0831843A1 (en) * 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
DE69726879T2 (de) * 1996-05-17 2004-10-14 Merck & Co., Inc. Biphosphonat-formulierung mit brausewirkung

Also Published As

Publication number Publication date
EP0998292B1 (en) 2001-11-21
JP2002502433A (ja) 2002-01-22
CN1299689C (zh) 2007-02-14
IS5315A (is) 1999-12-21
TR200000145T2 (tr) 2000-05-22
EP1175904A2 (en) 2002-01-30
ATE357921T1 (de) 2007-04-15
JP2005068010A (ja) 2005-03-17
CN1265035A (zh) 2000-08-30
EP1175904B8 (en) 2007-05-09
ID24096A (id) 2000-07-06
PT1175904E (pt) 2007-04-30
EP1175903A3 (en) 2002-12-18
DK1175904T3 (da) 2007-05-07
PL338635A1 (en) 2000-11-06
EE200000040A (et) 2000-10-16
EP1151752A2 (en) 2001-11-07
EP0998292A2 (en) 2000-05-10
NZ501807A (en) 2003-02-28
SK932000A3 (en) 2000-09-12
HK1040494A1 (en) 2002-06-14
EA004544B1 (ru) 2004-06-24
CN1602880A (zh) 2005-04-06
EP1132088A3 (en) 2002-04-24
KR100391732B1 (ko) 2003-07-16
ATE209037T1 (de) 2001-12-15
DE69837450D1 (de) 2007-05-10
SG109478A1 (en) 2005-03-30
KR20030097611A (ko) 2003-12-31
EA200000151A1 (ru) 2000-10-30
BG66282B1 (bg) 2013-01-31
DE122006000009I1 (de) 2006-06-14
EP1175904B1 (en) 2007-03-28
CN1166365C (zh) 2004-09-15
CY2007022I2 (el) 2012-01-25
ES2269014T1 (es) 2007-04-01
DE122007000063I1 (de) 2007-12-20
ES2269014T3 (es) 2007-05-01
NO20000323L (no) 2000-03-20
LU91364I2 (fr) 2007-11-12
EP1132088A2 (en) 2001-09-12
DE01201913T1 (de) 2007-02-08
PT998292E (pt) 2002-04-29
IS7230A (is) 2004-04-21
KR20010022110A (ko) 2001-03-15
CA2294595C (en) 2001-08-21
EP1175904A3 (en) 2002-12-18
LU91222I2 (fr) 2006-04-18
ES2253136T1 (es) 2006-06-01
IS7231A (is) 2004-04-21
EA004544B2 (ru) 2006-12-29
NL300292I1 (nl) 2007-11-01
DE69803291D1 (de) 2002-02-21
ES2164447T3 (es) 2002-02-16
HK1024166A1 (en) 2000-10-05
CY2007022I1 (el) 2012-01-25
WO1999004773A2 (en) 1999-02-04
CY1107535T1 (el) 2012-01-25
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
HK1042232A1 (en) 2002-08-09
NL300223I1 (nl) 2006-04-03
PL195272B1 (pl) 2007-08-31
JP3479780B2 (ja) 2003-12-15
SI0998292T1 (en) 2002-04-30
DE69837450T2 (de) 2007-08-23
UY25950A1 (es) 2000-09-29
EP1175903A2 (en) 2002-01-30
BG104093A (en) 2000-10-31
WO1999004773A9 (en) 1999-10-28
WO1999004773A3 (en) 1999-04-15
DE69803291T2 (de) 2002-08-08
HK1040495A1 (en) 2002-06-14
KR20030097610A (ko) 2003-12-31
HK1042230A1 (en) 2002-08-09
EP1151752A3 (en) 2002-12-18
IL133535A0 (en) 2001-04-30
CN1602879A (zh) 2005-04-06
DE01201911T1 (de) 2007-10-18
BR9810779A (pt) 2000-07-25
DK0998292T3 (da) 2002-05-13
EE05603B1 (et) 2012-12-17
CA2294595A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
US5994329A (en) Method for inhibiting bone resorption
US6015801A (en) Method for inhibiting bone resorption
US6465443B2 (en) Method for inhibiting bone resorption
CA2294595C (en) Inhibiting bone resorption
GB2336311A (en) Bisphosphonate Dosing Regimen
AU741818B2 (en) Method for inhibiting bone resorption
CA2349744A1 (en) Inhibition bone resorption
AU2451102A (en) Method for inhibiting bone resorption
AU1567702A (en) Method for inhibiting bone resorption
IL153109A (en) An effective pharmaceutical composition for inhibiting bone resorption in humans containing alendronic acid or its acceptable pharmaceutical salt or mixture
AU2005227418A1 (en) Method for inhibiting bone resorption
MXPA00000789A (en) Method for inhibiting bone resorption
HRP20000035A2 (en) Method for inhibiting bone resorption

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted